SCHEMBL4238995

SCHEMBL4238995

NC(c1ccccc1-c1ccccc1C(=O)NCCc1ccccn1)S(=O)(=O)c1cccc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KCNA5 P22460 5/20 0.45
KCNA3 P22001 2/20 0.44
KCNK3 O14649 1/20 0.44
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
NAMPT P43490 1/20 0.42
ATM Q13315 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
SLC12A2 P55011 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244514 0.90 HTT (0.55) HTTCA2CA4KCNA5KCNA3
SCHEMBL4245385 0.86 RAB9A (0.46) CA2ALDH1A1KCNA5SMN1; SMN2NPC1
SCHEMBL4242916 0.81 CHRNB2 (0.46) HTTCA2CA4ALDH1A1KCNA5
SCHEMBL2208909 0.80 KCNA5 (0.56) HTTCA2CA4ALDH1A1KCNA5
SCHEMBL4240140 0.77 GBA1 (0.43) HTTALDH1A1MEN1KMT2ALMNA
SCHEMBL5444524 0.73 KCNA5 (0.66) HTTALDH1A1KCNA5KCNA3KCNK3
SCHEMBL4247417 0.73 ALDH1A1 (0.53) CA2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL2211818 0.73 KCNA5 (0.49) HTTALDH1A1KCNA5KCNA3KCNK3
SCHEMBL20333475 0.72 LMNA (0.48) HTTKCNA5KCNA3KCNK3KDM4E
SCHEMBL5451241 0.71 KCNA5 (0.68) HTTALDH1A1KCNA5KCNA3KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 HTT 3641/4885CA2 1130/4885CA4 2665/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E HTT 3617/4885CA2 1135/4885CA4 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.